There is an urgent clinical need for new biomarkers in hepatocellular carcinoma, including better tools for early tumor detection and prediction of response to systemic therapies.

The International Liver Cancer Association has put together an exceptional team of experts led by Drs. Villanueva and Singal, who recently published a white paper with recommendations on the design, interpretation and reporting of biomarker studies in hepatocellular carcinoma. This addresses the much needed guidance for academia and industry on the best approach to develop new biomarkers for this devastating disease.

Read the paper here